차세대 시퀀싱 서비스 시장 규모, 점유율, 동향 분석 보고서 : 서비스 종류별, 워크플로우별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Next-generation Sequencing Services Market Summary

The global next-generation sequencing services market size was estimated at USD 6.66 billion in 2024 and is anticipated to reach USD 40.43 billion by 2033, expanding at a CAGR of 22.54% from 2025 to 2033. This growth is driven by the increasing demand for advanced genomic research, the rising prevalence of genetic disorders, and the growing adoption of precision medicine.

Increased Prevalence of Genetic and Chronic Diseases

One of the most significant drivers fueling demand in the next-generation sequencing (NGS) services industry is the rising global burden of genetic and chronic diseases. Conditions such as cancer, cardiovascular diseases, neurological disorders, and rare inherited syndromes are increasing in prevalence, prompting a heightened need for advanced diagnostic tools. Traditional diagnostic methods often fail to identify the underlying genetic causes of complex diseases, whereas NGS offers comprehensive genomic insights that enable early detection and precise diagnosis. For instance, according to data from the Centers for Disease Control and Prevention (CDC), 6 out of 10 Americans suffer from at least one chronic illness. At the same time, 4 out of 10 are affected by two or more chronic conditions. As healthcare systems worldwide shift toward preventive and precision medicine, the demand for robust, accurate, and scalable sequencing services continues to surge.

Rare genetic disorders, often undiagnosed due to their complexity and rarity, can now be effectively identified through whole-genome and exome sequencing provided by NGS services. For example, NGS can detect somatic mutations in cancer patients, facilitating the development of personalized treatment plans and improving patient outcomes. Moreover, as more individuals seek comprehensive genetic information to understand disease risks and inform their healthcare decisions, clinical laboratories, hospitals, and research institutions are increasingly becoming specialized NGS service providers. This trend is expected to intensify during the forecast period, positioning NGS services as an indispensable tool in the global fight against chronic and hereditary diseases.

Global Next-Generation Sequencing Services Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the next-generation sequencing services market on the basis of service type, workflow, end use, and region:

• Service Type Outlook (Revenue, USD Million, 2021 - 2033)
• Human Genome Sequencing Services
• Single Cell Sequencing Services
• Microbial Genome-based Sequencing Services
• Gene Regulation Services
  • Small RNA Sequencing
  • ChIP Sequencing
  • Other Gene Regulation-based Services
• Animal & Plant Sequencing Services
• Other Sequencing Services
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-sequencing
• Sequencing
• Data Analysis
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Universities & Other Research Entities
• Hospitals & Clinics
• Pharma & Biotech Entities
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Switzerland
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Singapore
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Information analysis
  • 1.2.2. Market formulation & data visualization
  • 1.2.3. Data validation & publishing
• 1.3. Information Procurement
  • 1.3.1. Primary Others
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Market Model
• 1.7. Objectives
  • 1.7.1. Objective 1
  • 1.7.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Derivers
  • 3.3.1. Increased Prevalence of Genetic and Chronic Diseases
  • 3.3.2. Rising emphasis on quality control and safety
• 3.4. Market Restraint Analysis
  • 3.4.1. Challenges pertaining to the implementation of large-scale NGS analysis workflows
  • 3.4.2. Analytical challenges in single-cell sequencing
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Service Type Business Analysis

• 4.1. Global Next-Generation Sequencing Services Market: Service Type Movement Analysis
• 4.2. Human Genome Sequencing Services
  • 4.2.1. Human Genome Sequencing Services Market, 2021 - 2033 (USD Million)
• 4.3. Single-Cell Sequencing Services
  • 4.3.1. Single-Cell Sequencing Services Market, 2021 - 2033 (USD Million)
• 4.4. Microbial Genome-based Sequencing Services
  • 4.4.1. Microbial Genome-based Sequencing Services Market, 2021 - 2033 (USD Million)
• 4.5. Gene Regulation Services
  • 4.5.1. Gene Regulation Services Market, 2021 - 2033 (USD Million)
  • 4.5.2. Small RNA Sequencing Services
    • 4.5.2.1. Small RNA Sequencing Services Market, 2021 - 2033 (USD Million)
  • 4.5.3. Chip Sequencing Services
    • 4.5.3.1. Chip Sequencing Services Market, 2021 - 2033 (USD Million)
  • 4.5.4. Other Gene Regulation-based Service
    • 4.5.4.1. Other Gene Regulation-based Service Market, 2021 - 2033 (USD Million)
• 4.6. Animal & Plant Sequencing Services
  • 4.6.1. Animal & Plant Sequencing Services Market, 2021 - 2033 (USD Million)
• 4.7. Other Sequencing Services
  • 4.7.1. Other Sequencing Services Market, 2021 - 2033 (USD Million)

Chapter 5. Workflow Business Analysis

• 5.1. Global Next-Generation Sequencing Services Market: Workflow Movement Analysis
• 5.2. Pre Sequencing Service
  • 5.2.1. Pre Sequencing Service Market, 2021 - 2033 (USD Million)
• 5.3. Sequencing Service
  • 5.3.1. Sequencing Service Market, 2021 - 2033 (USD Million)
• 5.4. Data Analysis Service
  • 5.4.1. Data Analysis Service Market, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. Global Next-Generation Sequencing Services Market: End Use Movement Analysis
• 6.2. Universities & Other Research Entities
  • 6.2.1. Universities & Other Research Entities Market, 2021 - 2033 (USD Million)
• 6.3. Hospitals & Clinics
  • 6.3.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
• 6.4. Pharma & Biotech Entities
  • 6.4.1. Pharma & Biotech Entities Market, 2021 - 2033 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Global Next-Generation Sequencing Services Market Share, By Region, 2024 & 2033
• 7.2. North America
  • 7.2.1. North America Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Competitive Scenario
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Target Disease Prevalence
    • 7.2.2.5. U.S. Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Competitive Scenario
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Target Disease Prevalence
    • 7.2.3.5. Canada Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Competitive Scenario
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Target Disease Prevalence
    • 7.2.4.5. Mexico Next-generation sequencing services market, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.3.2. Germany
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Target Disease Prevalence
    • 7.3.2.5. Germany Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.3.3. UK
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Target Disease Prevalence
    • 7.3.3.5. UK Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Target Disease Prevalence
    • 7.3.4.5. France Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Competitive Scenario
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Target Disease Prevalence
    • 7.3.5.5. Italy Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Competitive Scenario
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Target Disease Prevalence
    • 7.3.6.5. Spain Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Competitive Scenario
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Target Disease Prevalence
    • 7.3.7.5. Denmark Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Competitive Scenario
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Target Disease Prevalence
    • 7.3.8.5. Sweden Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Competitive Scenario
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Target Disease Prevalence
    • 7.3.9.5. Norway Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.3.10. Switzerland
    • 7.3.10.1. Key Country Dynamics
    • 7.3.10.2. Competitive Scenario
    • 7.3.10.3. Regulatory Framework
    • 7.3.10.4. Target Disease Prevalence
    • 7.3.10.5. Switzerland Next-generation sequencing services market, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Target Disease Prevalence
    • 7.4.2.5. Japan Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Target Disease Prevalence
    • 7.4.3.5. China Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Target Disease Prevalence
    • 7.4.4.5. India Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Target Disease Prevalence
    • 7.4.5.5. South Korea Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Target Disease Prevalence
    • 7.4.6.5. Australia Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Target Disease Prevalence
    • 7.4.7.5. Thailand Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.4.8. Singapore
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Target Disease Prevalence
    • 7.4.8.5. Singapore Next-generation sequencing services market, 2021 - 2033 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Target Disease Prevalence
    • 7.5.2.5. Brazil Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Target Disease Prevalence
    • 7.5.3.5. Argentina Next-generation sequencing services market, 2021 - 2033 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Target Disease Prevalence
    • 7.6.2.5. South Africa Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Target Disease Prevalence
    • 7.6.3.5. Saudi Arabia Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Target Disease Prevalence
    • 7.6.4.5. UAE Next-generation sequencing services market, 2021 - 2033 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Target Disease Prevalence
    • 7.6.5.5. Kuwait Next-generation sequencing services market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market/Position Share Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Illumina, Inc.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Thermo Fisher Scientific Inc.
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. BGI Genomics
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Eurofins Genomics
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. GENEWIZ
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Macrogen Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. QIAGEN N.V.
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Agilent Technologies Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Revvity, Inc.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Twist Bioscience
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives